RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
|Videos|September 15, 2020
Investigational Treatment Shows Potential to Supress Memory Loss
Author(s)Aaron H. Burstein, PharmD
Aaron Burstein, PharmD, shares details from a scientific presentation at the Alzheimer's Association International Conference.
Advertisement
MENTAL HEALTH MINUTE
Aaron Burstein, PharmD, senior vice president of
Advertisement
Related to this article
Cardiologist Mary Branch, MD, reveals how depression, meds, and food insecurity shape heart risk—and why cardiology-psychiatry teamwork matters.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
5